La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Syndax Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
Syndax Pharmaceuticals' CEO is Michael Metzger, appointed in Feb 2022, has a tenure of 2.5 years. total yearly compensation is $9.13M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth $1.05M. The average tenure of the management team and the board of directors is 2.2 years and 8.1 years respectively.
Informations clés
Michael Metzger
Directeur général
US$9.1m
Rémunération totale
Pourcentage du salaire du PDG | 7.4% |
Durée du mandat du directeur général | 2.5yrs |
Propriété du PDG | 0.06% |
Durée moyenne d'occupation des postes de direction | 2.2yrs |
Durée moyenne du mandat des membres du conseil d'administration | 8.1yrs |
Mises à jour récentes de la gestion
Recent updates
Syndax: Gearing Up For Launches
Jun 21Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Jun 20Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Mar 28Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Mar 04Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Nov 20Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Sep 27Syndax Pharmaceuticals Q2 2022 Earnings Preview
Aug 07Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Apr 08Analyse de la rémunération des PDG
Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$264m |
Mar 31 2024 | n/a | n/a | -US$241m |
Dec 31 2023 | US$9m | US$678k | -US$209m |
Sep 30 2023 | n/a | n/a | -US$176m |
Jun 30 2023 | n/a | n/a | -US$160m |
Mar 31 2023 | n/a | n/a | -US$153m |
Dec 31 2022 | US$4m | US$640k | -US$149m |
Sep 30 2022 | n/a | n/a | -US$14m |
Jun 30 2022 | n/a | n/a | US$818k |
Mar 31 2022 | n/a | n/a | US$15m |
Dec 31 2021 | US$3m | US$594k | US$25m |
Sep 30 2021 | n/a | n/a | -US$92m |
Jun 30 2021 | n/a | n/a | -US$91m |
Mar 31 2021 | n/a | n/a | -US$86m |
Dec 31 2020 | US$2m | US$577k | -US$77m |
Sep 30 2020 | n/a | n/a | -US$71m |
Jun 30 2020 | n/a | n/a | -US$63m |
Mar 31 2020 | n/a | n/a | -US$61m |
Dec 31 2019 | US$3m | US$540k | -US$56m |
Sep 30 2019 | n/a | n/a | -US$61m |
Jun 30 2019 | n/a | n/a | -US$65m |
Mar 31 2019 | n/a | n/a | -US$69m |
Dec 31 2018 | US$2m | US$506k | -US$74m |
Sep 30 2018 | n/a | n/a | -US$74m |
Jun 30 2018 | n/a | n/a | -US$72m |
Mar 31 2018 | n/a | n/a | -US$67m |
Dec 31 2017 | US$1m | US$492k | -US$61m |
Rémunération vs marché: Michael's total compensation ($USD9.13M) is above average for companies of similar size in the US market ($USD5.62M).
Rémunération et revenus: Michael's compensation has increased whilst the company is unprofitable.
PDG
Michael Metzger (53 yo)
2.5yrs
Titularisation
US$9,127,419
Compensation
Mr. Michael A. Metzger is a Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer and as a member of the Boa...
Équipe de direction
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
CEO & Director | 2.5yrs | US$9.13m | 0.062% $ 1.1m | |
President | 1.3yrs | US$4.04m | 0.015% $ 261.5k | |
CFO, Treasurer & Chief Accounting Officer | 2.2yrs | US$2.83m | 0.021% $ 351.2k | |
Senior VP | 8yrs | US$2.59m | 0.051% $ 862.2k | |
Chief Medical Officer | 2.4yrs | US$2.81m | 0.042% $ 720.1k | |
Co-Founder & Chief Scientific Officer | 18.8yrs | pas de données | 0.00031% $ 5.3k | |
Co-Founder | no data | pas de données | pas de données | |
Co-Founder | no data | pas de données | pas de données | |
Co-Founder | no data | pas de données | pas de données | |
Vice President of Investor Relations & Communications | 2.2yrs | pas de données | pas de données | |
Chief People Officer | 1.3yrs | pas de données | pas de données | |
Member of Scientific Advisory Board & Chief Medical Officer | 1.7yrs | pas de données | pas de données |
2.2yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: SNDX's management team is considered experienced (2.2 years average tenure).
Membres du conseil d'administration
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
CEO & Director | 5.1yrs | US$9.13m | 0.062% $ 1.1m | |
Co-Founder | 8.1yrs | pas de données | pas de données | |
Member of Scientific Advisory Board & Chief Medical Officer | 8.1yrs | pas de données | pas de données | |
Independent Director | 7.4yrs | US$581.02k | 0.038% $ 637.7k | |
Independent Director | 7.6yrs | US$575.59k | 0.038% $ 637.7k | |
Independent Chairman | 15.7yrs | US$1.10m | 0.017% $ 287.6k | |
Member of Scientific Advisory Board | 7.3yrs | US$23.05k | pas de données | |
Member of Scientific Advisory Board | 8.1yrs | pas de données | pas de données | |
Member of Scientific Advisory Board | 8.1yrs | pas de données | pas de données | |
Member of Scientific Advisory Board | 8.1yrs | pas de données | pas de données | |
Member of Scientific Advisory Board | 8.7yrs | pas de données | pas de données | |
Member of Scientific Advisory Board | 7.6yrs | pas de données | pas de données |
8.1yrs
Durée moyenne de l'emploi
64yo
Âge moyen
Conseil d'administration expérimenté: SNDX's board of directors are considered experienced (8.1 years average tenure).